Drugs / telomerase: 540-548 peptide vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00079157 | Feb 2004 → Dec 2007 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00069940 | Dec 2000 → Aug 2006 | central nervous system neoplasm, gastrointestinal stromal tumor, sarcoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | telomerase: 540-548 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069940 ↗ |
| Modality | Vaccine | “telomerase: 540-548 peptide vaccine” NCT00069940 ↗ |
| Route | Subcutaneous | “telomerase: 540-548 peptide vaccine subcutaneously (SC) on day 3” NCT00069940 ↗ |